



## Краткая информация о проекте

Наименование	AP19675905 «Исследование иммуногенетических и клинических предикторов иммунопатологии, инфекционных и аутоиммунных заболеваний после перенесённой SARSCov2-инфекции»
Актуальность	Проект открывает возможности для разработки критерий быстрого прогрессирования поражения органов и систем при пост-COVID19 синдромах (ДБСТ, васкулиты, гепатиты и т.п.) для выбора тактики лечения и предупреждения осложнений и неблагоприятных исходов больных на основе анализа полученных данных.
Цель	Целью проекта является изучение иммуногенетики, иммунологических параметров, клинических особенностей течения иммунопатологии (инфекционной, аутоиммунной, лимфопролиферативной), у пациентов в отдаленный период после перенесенной SARSCov-2-инфекции.
Задачи	<ol style="list-style-type: none"> <li>1) Изучить процесс восстановления функции иммунной системы (CD-профиль и функциональное лимфоцитов периферической крови) больных, перенесших COVID19 в динамике инфекционного процесса в период от нескольких месяцев до двух лет.</li> <li>2) Изучить варианты развития SARSCov-2 ассоциированной иммунопатологии в связи с характером и выраженностью нарушений в иммунорегуляции в пост-COVID19 период (нарушение процесса восстановления функций иммунной системы в период реконвалесценции COVID19)</li> <li>3) Изучить клинические варианты SARSCov-2 ассоциированной иммунопатологии (мультисистемный воспалительный синдром, системные SARSCov-2-ассоциированные васкулиты и ДБСТ-подобные синдромы, реактивация хронических персистирующих инфекций), их отличие от типичного течения при других заболеваниях и состояниях</li> <li>4) Описать клинико-иммунологические особенности пост-COVID19 у людей, варианты развития иммунопатологических событий, в том числе фатальных с разработкой факторов риска неблагоприятных событий – генетических, иммунологических, клинических.</li> <li>5) Разработать прогностические иммуногенетические и иммунологические критерии быстрого прогрессирования поражения органов и систем при пост-COVID19 синдромах (ДБСТ, васкулиты, гепатиты и т.п.) для выбора тактики лечения и предупреждения осложнений и неблагоприятных исходов больных на основе анализа полученных данных.</li> </ol>
Ожидаемые и достигнутые результаты	<ol style="list-style-type: none"> <li>1. Будет разработана карта регистрации клинических данных и иммунологических параметров.</li> <li>2. Будет проведен аналитический обзор по иммунному ответу и 2023г иммунопатологическим изменениям при COVID19.</li> <li>3. Будут проведены работы по проведению клинического обследования и анализа медицинской документации больных в стационаре, рандомизация и отбор больных для углубленного обследования по критериям включения и исключения.</li> <li>4. Будут представлены данные по научной теме не менее в 2 международных конгрессах и не менее 2 отечественных конференциях.</li> <li>5. За весь период реализации проекта будут подготовлены и опубликованы статьи рейтинговых журналах согласно требованиям конкурсной документации: - не мене 3 (трех) статей и (или) обзоров в рецензируемых научных</li> </ol>

	<p>изданиях, индексируемых в Science Citation Index Expanded базы Web of Science и (или) имеющих проценты по CiteScore в базе Scopus не менее 35 (тридцати пяти);</p> <ul style="list-style-type: none"> <li>- а также не менее 1 (одной) статьи или обзора в рецензируемом зарубежном или отечественном издании, рекомендованном КОКСНВО;</li> <li>- либо не менее 2 (двух) статей и (или) обзоров рецензируемых научных изданий, индексируемых в Science Citation Index Expanded и входящих в 1 (первый) и (или) 2 (второй) квартиль по импакт- фактору в базе Web of Science и (или) имеющих проценты по Cite Score в базе Scopus не менее 65 (шестидесяти пяти);</li> <li>- либо не мене 1 (одной) статьи или обзора рецензируемом научном издании, индексируемом в Science Citation Index Expanded и входящем в 1 (первый) квартиль по импакт-фактору в базе Web of Science и (или) имеющем проценты CiteScore в базе Scopus не менее 80 (восемидесяти).</li> </ul>
<p>Имена и фамилии членов исследовательской группы с их идентификаторами (Scopus Author ID, Researcher ID, ORCID, при наличии) и ссылками на соответствующие профили</p>	<ol style="list-style-type: none"> <li>1. Тримова Гульжан Шакрафовна, PhD, Индекс Хирша – 5, Researcher ID, ORCID: 0000-0001-8130-4150, Scopus author ID: 56556992400</li> <li>2. Курманова Гаухар Медеубаевна, д.м.н., профессор, Индекс Хирша – 2; ORCID: 0000-0002-5768-0209, Scopus Author ID: 6507474504.</li> <li>3. Кулембаева Анаркуль Бакировна, к.м.н.</li> <li>4. Идрисова Гульжан Максutowна</li> <li>5. Бейсебаева Алия Кайратовна</li> <li>6. Рахимбаева Мадина Сакеновна</li> </ol>
<p>Список публикаций со ссылками на них</p>	<p>«Сравнительная характеристика течения covid-19 в 2020-2021 годы в городе Алматы», Doi 10.53511/Pharmkaz.2024.11.87.007 А.М. Курманова, А.Е. Каримсакова, Г.М. Курманова, Г.Ш. Тримова</p>
<p>Информация о патентах</p>	<p>-</p>





25th Asia-Pacific League of Associations of Rheumatology Congress  
Thailand, Bangkok, 13-17 September 2021

76

### A case of spontaneous pneumothorax and subcutaneous emphysema in the onset of SLE following Covid-19

G. Tripathi<sup>1</sup>, G. Kumar<sup>2</sup>, G. Kishore<sup>3</sup>, G. Srinivasan<sup>4</sup>, G. Srinivasan<sup>5</sup>, G. Srinivasan<sup>6</sup>, G. Srinivasan<sup>7</sup>, G. Srinivasan<sup>8</sup>, G. Srinivasan<sup>9</sup>, G. Srinivasan<sup>10</sup>

**Introduction**  
Free cases of the onset of systemic lupus erythematosus (SLE) have been reported after Covid-19. Spontaneous pneumothorax and subcutaneous emphysema are rare manifestations of the onset of SLE. We describe a case of SLE with both spontaneous pneumothorax and subcutaneous emphysema in the onset of SLE following Covid-19.

**Case presentation**  
A 35-year-old female patient presented with a 2-week history of low-grade fever, cough, and shortness of breath. She was diagnosed with Covid-19. During her recovery, she developed spontaneous pneumothorax and subcutaneous emphysema. She was treated with corticosteroids and oxygen. She was discharged and followed up. She was diagnosed with SLE. She was treated with corticosteroids and immunosuppressants. She was followed up and her symptoms improved.

**Laboratory tests**  
Anti-nuclear antibody (ANA): Positive  
Anti-double-stranded DNA (dsDNA): Positive  
Anti-Smith antibody (Anti-Sm): Positive  
Anti-cardiolipin antibody (Anti-CLA): Positive  
Anti-phospholipase A2 antibody (Anti-PLA2): Positive  
Anti-β2-glycoprotein I antibody (Anti-β2GPI): Positive  
Anti-oxidized LDL antibody (Anti-oxLDL): Positive  
Anti-protein C antibody (Anti-PC): Positive  
Anti-protein S antibody (Anti-PS): Positive  
Anti-tissue factor pathway inhibitor antibody (Anti-TFPI): Positive  
Anti-thrombin-3 antibody (Anti-T3): Positive  
Anti-thrombin-4 antibody (Anti-T4): Positive  
Anti-thrombin-5 antibody (Anti-T5): Positive  
Anti-thrombin-6 antibody (Anti-T6): Positive  
Anti-thrombin-7 antibody (Anti-T7): Positive  
Anti-thrombin-8 antibody (Anti-T8): Positive  
Anti-thrombin-9 antibody (Anti-T9): Positive  
Anti-thrombin-10 antibody (Anti-T10): Positive  
Anti-thrombin-11 antibody (Anti-T11): Positive  
Anti-thrombin-12 antibody (Anti-T12): Positive  
Anti-thrombin-13 antibody (Anti-T13): Positive  
Anti-thrombin-14 antibody (Anti-T14): Positive  
Anti-thrombin-15 antibody (Anti-T15): Positive  
Anti-thrombin-16 antibody (Anti-T16): Positive  
Anti-thrombin-17 antibody (Anti-T17): Positive  
Anti-thrombin-18 antibody (Anti-T18): Positive  
Anti-thrombin-19 antibody (Anti-T19): Positive  
Anti-thrombin-20 antibody (Anti-T20): Positive  
Anti-thrombin-21 antibody (Anti-T21): Positive  
Anti-thrombin-22 antibody (Anti-T22): Positive  
Anti-thrombin-23 antibody (Anti-T23): Positive  
Anti-thrombin-24 antibody (Anti-T24): Positive  
Anti-thrombin-25 antibody (Anti-T25): Positive  
Anti-thrombin-26 antibody (Anti-T26): Positive  
Anti-thrombin-27 antibody (Anti-T27): Positive  
Anti-thrombin-28 antibody (Anti-T28): Positive  
Anti-thrombin-29 antibody (Anti-T29): Positive  
Anti-thrombin-30 antibody (Anti-T30): Positive  
Anti-thrombin-31 antibody (Anti-T31): Positive  
Anti-thrombin-32 antibody (Anti-T32): Positive  
Anti-thrombin-33 antibody (Anti-T33): Positive  
Anti-thrombin-34 antibody (Anti-T34): Positive  
Anti-thrombin-35 antibody (Anti-T35): Positive  
Anti-thrombin-36 antibody (Anti-T36): Positive  
Anti-thrombin-37 antibody (Anti-T37): Positive  
Anti-thrombin-38 antibody (Anti-T38): Positive  
Anti-thrombin-39 antibody (Anti-T39): Positive  
Anti-thrombin-40 antibody (Anti-T40): Positive  
Anti-thrombin-41 antibody (Anti-T41): Positive  
Anti-thrombin-42 antibody (Anti-T42): Positive  
Anti-thrombin-43 antibody (Anti-T43): Positive  
Anti-thrombin-44 antibody (Anti-T44): Positive  
Anti-thrombin-45 antibody (Anti-T45): Positive  
Anti-thrombin-46 antibody (Anti-T46): Positive  
Anti-thrombin-47 antibody (Anti-T47): Positive  
Anti-thrombin-48 antibody (Anti-T48): Positive  
Anti-thrombin-49 antibody (Anti-T49): Positive  
Anti-thrombin-50 antibody (Anti-T50): Positive  
Anti-thrombin-51 antibody (Anti-T51): Positive  
Anti-thrombin-52 antibody (Anti-T52): Positive  
Anti-thrombin-53 antibody (Anti-T53): Positive  
Anti-thrombin-54 antibody (Anti-T54): Positive  
Anti-thrombin-55 antibody (Anti-T55): Positive  
Anti-thrombin-56 antibody (Anti-T56): Positive  
Anti-thrombin-57 antibody (Anti-T57): Positive  
Anti-thrombin-58 antibody (Anti-T58): Positive  
Anti-thrombin-59 antibody (Anti-T59): Positive  
Anti-thrombin-60 antibody (Anti-T60): Positive  
Anti-thrombin-61 antibody (Anti-T61): Positive  
Anti-thrombin-62 antibody (Anti-T62): Positive  
Anti-thrombin-63 antibody (Anti-T63): Positive  
Anti-thrombin-64 antibody (Anti-T64): Positive  
Anti-thrombin-65 antibody (Anti-T65): Positive  
Anti-thrombin-66 antibody (Anti-T66): Positive  
Anti-thrombin-67 antibody (Anti-T67): Positive  
Anti-thrombin-68 antibody (Anti-T68): Positive  
Anti-thrombin-69 antibody (Anti-T69): Positive  
Anti-thrombin-70 antibody (Anti-T70): Positive  
Anti-thrombin-71 antibody (Anti-T71): Positive  
Anti-thrombin-72 antibody (Anti-T72): Positive  
Anti-thrombin-73 antibody (Anti-T73): Positive  
Anti-thrombin-74 antibody (Anti-T74): Positive  
Anti-thrombin-75 antibody (Anti-T75): Positive  
Anti-thrombin-76 antibody (Anti-T76): Positive  
Anti-thrombin-77 antibody (Anti-T77): Positive  
Anti-thrombin-78 antibody (Anti-T78): Positive  
Anti-thrombin-79 antibody (Anti-T79): Positive  
Anti-thrombin-80 antibody (Anti-T80): Positive  
Anti-thrombin-81 antibody (Anti-T81): Positive  
Anti-thrombin-82 antibody (Anti-T82): Positive  
Anti-thrombin-83 antibody (Anti-T83): Positive  
Anti-thrombin-84 antibody (Anti-T84): Positive  
Anti-thrombin-85 antibody (Anti-T85): Positive  
Anti-thrombin-86 antibody (Anti-T86): Positive  
Anti-thrombin-87 antibody (Anti-T87): Positive  
Anti-thrombin-88 antibody (Anti-T88): Positive  
Anti-thrombin-89 antibody (Anti-T89): Positive  
Anti-thrombin-90 antibody (Anti-T90): Positive  
Anti-thrombin-91 antibody (Anti-T91): Positive  
Anti-thrombin-92 antibody (Anti-T92): Positive  
Anti-thrombin-93 antibody (Anti-T93): Positive  
Anti-thrombin-94 antibody (Anti-T94): Positive  
Anti-thrombin-95 antibody (Anti-T95): Positive  
Anti-thrombin-96 antibody (Anti-T96): Positive  
Anti-thrombin-97 antibody (Anti-T97): Positive  
Anti-thrombin-98 antibody (Anti-T98): Positive  
Anti-thrombin-99 antibody (Anti-T99): Positive  
Anti-thrombin-100 antibody (Anti-T100): Positive

aplarcongress.com

25th Asia-Pacific League of Associations of Rheumatology Congress  
Thailand, Bangkok, 13-17 September 2021

77

### Mixed connective tissue disease as the onset after Covid-19

G. Tripathi<sup>1</sup>, G. Kumar<sup>2</sup>, G. Kishore<sup>3</sup>, G. Srinivasan<sup>4</sup>, G. Srinivasan<sup>5</sup>, G. Srinivasan<sup>6</sup>, G. Srinivasan<sup>7</sup>, G. Srinivasan<sup>8</sup>, G. Srinivasan<sup>9</sup>, G. Srinivasan<sup>10</sup>

**Introduction**  
Mixed connective tissue disease (MCTD) is a systemic disorder which has features of systemic lupus erythematosus (SLE), scleroderma, and polymyositis. It is characterized by the presence of anti-U1-RNP antibody. We have described two cases of onset and relapse of MCTD following Covid-19.

**Case presentation #1**  
A 45-year-old female patient presented with a 2-week history of low-grade fever, cough, and shortness of breath. She was diagnosed with Covid-19. During her recovery, she developed symptoms of MCTD. She was treated with corticosteroids and immunosuppressants. She was followed up and her symptoms improved.

**Case presentation #2**  
A 55-year-old female patient presented with a 2-week history of low-grade fever, cough, and shortness of breath. She was diagnosed with Covid-19. During her recovery, she developed symptoms of MCTD. She was treated with corticosteroids and immunosuppressants. She was followed up and her symptoms improved.

**Laboratory tests**  
Anti-nuclear antibody (ANA): Positive  
Anti-double-stranded DNA (dsDNA): Positive  
Anti-Smith antibody (Anti-Sm): Positive  
Anti-cardiolipin antibody (Anti-CLA): Positive  
Anti-phospholipase A2 antibody (Anti-PLA2): Positive  
Anti-β2-glycoprotein I antibody (Anti-β2GPI): Positive  
Anti-oxidized LDL antibody (Anti-oxLDL): Positive  
Anti-protein C antibody (Anti-PC): Positive  
Anti-protein S antibody (Anti-PS): Positive  
Anti-tissue factor pathway inhibitor antibody (Anti-TFPI): Positive  
Anti-thrombin-3 antibody (Anti-T3): Positive  
Anti-thrombin-4 antibody (Anti-T4): Positive  
Anti-thrombin-5 antibody (Anti-T5): Positive  
Anti-thrombin-6 antibody (Anti-T6): Positive  
Anti-thrombin-7 antibody (Anti-T7): Positive  
Anti-thrombin-8 antibody (Anti-T8): Positive  
Anti-thrombin-9 antibody (Anti-T9): Positive  
Anti-thrombin-10 antibody (Anti-T10): Positive  
Anti-thrombin-11 antibody (Anti-T11): Positive  
Anti-thrombin-12 antibody (Anti-T12): Positive  
Anti-thrombin-13 antibody (Anti-T13): Positive  
Anti-thrombin-14 antibody (Anti-T14): Positive  
Anti-thrombin-15 antibody (Anti-T15): Positive  
Anti-thrombin-16 antibody (Anti-T16): Positive  
Anti-thrombin-17 antibody (Anti-T17): Positive  
Anti-thrombin-18 antibody (Anti-T18): Positive  
Anti-thrombin-19 antibody (Anti-T19): Positive  
Anti-thrombin-20 antibody (Anti-T20): Positive  
Anti-thrombin-21 antibody (Anti-T21): Positive  
Anti-thrombin-22 antibody (Anti-T22): Positive  
Anti-thrombin-23 antibody (Anti-T23): Positive  
Anti-thrombin-24 antibody (Anti-T24): Positive  
Anti-thrombin-25 antibody (Anti-T25): Positive  
Anti-thrombin-26 antibody (Anti-T26): Positive  
Anti-thrombin-27 antibody (Anti-T27): Positive  
Anti-thrombin-28 antibody (Anti-T28): Positive  
Anti-thrombin-29 antibody (Anti-T29): Positive  
Anti-thrombin-30 antibody (Anti-T30): Positive  
Anti-thrombin-31 antibody (Anti-T31): Positive  
Anti-thrombin-32 antibody (Anti-T32): Positive  
Anti-thrombin-33 antibody (Anti-T33): Positive  
Anti-thrombin-34 antibody (Anti-T34): Positive  
Anti-thrombin-35 antibody (Anti-T35): Positive  
Anti-thrombin-36 antibody (Anti-T36): Positive  
Anti-thrombin-37 antibody (Anti-T37): Positive  
Anti-thrombin-38 antibody (Anti-T38): Positive  
Anti-thrombin-39 antibody (Anti-T39): Positive  
Anti-thrombin-40 antibody (Anti-T40): Positive  
Anti-thrombin-41 antibody (Anti-T41): Positive  
Anti-thrombin-42 antibody (Anti-T42): Positive  
Anti-thrombin-43 antibody (Anti-T43): Positive  
Anti-thrombin-44 antibody (Anti-T44): Positive  
Anti-thrombin-45 antibody (Anti-T45): Positive  
Anti-thrombin-46 antibody (Anti-T46): Positive  
Anti-thrombin-47 antibody (Anti-T47): Positive  
Anti-thrombin-48 antibody (Anti-T48): Positive  
Anti-thrombin-49 antibody (Anti-T49): Positive  
Anti-thrombin-50 antibody (Anti-T50): Positive  
Anti-thrombin-51 antibody (Anti-T51): Positive  
Anti-thrombin-52 antibody (Anti-T52): Positive  
Anti-thrombin-53 antibody (Anti-T53): Positive  
Anti-thrombin-54 antibody (Anti-T54): Positive  
Anti-thrombin-55 antibody (Anti-T55): Positive  
Anti-thrombin-56 antibody (Anti-T56): Positive  
Anti-thrombin-57 antibody (Anti-T57): Positive  
Anti-thrombin-58 antibody (Anti-T58): Positive  
Anti-thrombin-59 antibody (Anti-T59): Positive  
Anti-thrombin-60 antibody (Anti-T60): Positive  
Anti-thrombin-61 antibody (Anti-T61): Positive  
Anti-thrombin-62 antibody (Anti-T62): Positive  
Anti-thrombin-63 antibody (Anti-T63): Positive  
Anti-thrombin-64 antibody (Anti-T64): Positive  
Anti-thrombin-65 antibody (Anti-T65): Positive  
Anti-thrombin-66 antibody (Anti-T66): Positive  
Anti-thrombin-67 antibody (Anti-T67): Positive  
Anti-thrombin-68 antibody (Anti-T68): Positive  
Anti-thrombin-69 antibody (Anti-T69): Positive  
Anti-thrombin-70 antibody (Anti-T70): Positive  
Anti-thrombin-71 antibody (Anti-T71): Positive  
Anti-thrombin-72 antibody (Anti-T72): Positive  
Anti-thrombin-73 antibody (Anti-T73): Positive  
Anti-thrombin-74 antibody (Anti-T74): Positive  
Anti-thrombin-75 antibody (Anti-T75): Positive  
Anti-thrombin-76 antibody (Anti-T76): Positive  
Anti-thrombin-77 antibody (Anti-T77): Positive  
Anti-thrombin-78 antibody (Anti-T78): Positive  
Anti-thrombin-79 antibody (Anti-T79): Positive  
Anti-thrombin-80 antibody (Anti-T80): Positive  
Anti-thrombin-81 antibody (Anti-T81): Positive  
Anti-thrombin-82 antibody (Anti-T82): Positive  
Anti-thrombin-83 antibody (Anti-T83): Positive  
Anti-thrombin-84 antibody (Anti-T84): Positive  
Anti-thrombin-85 antibody (Anti-T85): Positive  
Anti-thrombin-86 antibody (Anti-T86): Positive  
Anti-thrombin-87 antibody (Anti-T87): Positive  
Anti-thrombin-88 antibody (Anti-T88): Positive  
Anti-thrombin-89 antibody (Anti-T89): Positive  
Anti-thrombin-90 antibody (Anti-T90): Positive  
Anti-thrombin-91 antibody (Anti-T91): Positive  
Anti-thrombin-92 antibody (Anti-T92): Positive  
Anti-thrombin-93 antibody (Anti-T93): Positive  
Anti-thrombin-94 antibody (Anti-T94): Positive  
Anti-thrombin-95 antibody (Anti-T95): Positive  
Anti-thrombin-96 antibody (Anti-T96): Positive  
Anti-thrombin-97 antibody (Anti-T97): Positive  
Anti-thrombin-98 antibody (Anti-T98): Positive  
Anti-thrombin-99 antibody (Anti-T99): Positive  
Anti-thrombin-100 antibody (Anti-T100): Positive

Together Towards Tomorrow